There are two ways that OncoSec's price can be hit out of the park:
1. Extremely positive results from the trials.
2. A very lucrative buyout offer from a big pharma company.
In the absence of these, the pps will continue to wallow where it currently is or lower. OncoSec will have to prove itself, which it, obviously, has yet to do, to its doubters of which there are many.
$ONCS